Treatment of hyperproliferative disorders with diarylhydantoin compounds
The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
1. A method for treating a cancer comprising administering a therapeutically effective amount of a compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, thereby treating the cancer.
2. The method of claim 1 , further comprising administering an antiandrogen to the subject.
3. The method of claim 2 , wherein the composition is administered at a dosage of the compound in a range selected from the group consisting of from about 0.001 mg per kg body weight per day to about 100 mg per kg body weight per day, from about 0.01 mg per kg body weight per day to about 100 mg per kg body weight per day, and from about 0.1 mg per kg body weight per day to about 10 mg per kg body weight per day.
4. The method of claim 2 , wherein the composition is administered at a dosage of the compound of about 1 mg per kg body weight per day.
5. The method of claim 2 , wherein the compound is administered by intravenous injection, by injection into tissue, intraperitoneally, orally, or nasally.
6. The method of claim 2 , wherein the compound is in a form selected from the group consisting of a solution, dispersion, suspension, powder, capsule, tablet, pill, time release capsule, time release tablet, and time release pill.
7. The method of claim 1 , wherein the compound is
8. The method of claim 1 , wherein the compound is
9. The method of claim 1 , wherein the compound is
10. The method of claim 2 , wherein the compound is
11. The method of claim 2 , wherein the antiandrogen is selected from the group consisting of a non-steroidal antiandrogen and bicalutamide.
12. The method of claim 2 , wherein the cancer is selected from the group consisting of prostate cancer, hormone sensitive prostate cancer, and hormone refractory prostate cancer.
13. The method of claim 2 ,
wherein the cancer is prostate cancer and
wherein administering the compound prevents the prostate cancer from progressing to hormone refractory prostate cancer.
14. The method of claim 2 ,
wherein the cancer is hormone sensitive prostate cancer and
wherein administering the compound prevents the hormone sensitive prostate cancer from progressing to hormone refractory prostate cancer.
15. The method of claim 2 , wherein the cancer is selected from the group consisting of breast cancer, hormone sensitive breast cancer, and hormone refractory breast cancer.
16. The method of claim 2 ,
wherein the cancer is breast cancer and
wherein administering the compound prevents the breast cancer from progressing to hormone refractory breast cancer.
17. The method of claim 2 ,
wherein the cancer is hormone sensitive breast cancer and
wherein administering the compound prevents the hormone sensitive breast cancer from progressing to hormone refractory breast cancer.
18. The method of claim 2 , wherein the cancer is selected from the group consisting of ovarian cancer, hormone sensitive ovarian cancer, and hormone refractory ovarian cancer.
19. The method of claim 1 ,
further comprising administering an antiandrogen to the subject,
wherein the compound is administered after administering the antiandrogen.
20. The method of claim 19 , wherein the compound is
21. The method of claim 19 , wherein the antiandrogen is bicalutamide.
22. The method of claim 19 , wherein the cancer is selected from the group consisting of prostate cancer, hormone sensitive prostate cancer, hormone refractory prostate cancer, breast cancer, and ovarian cancer.
23. The method of claim 1 , further comprising administering an antiestrogen to the subject.
24. The method of claim 23 , wherein the compound is
25. The method of claim 23 , wherein the cancer is selected from the group consisting of breast cancer, hormone sensitive breast cancer, and hormone refractory breast cancer.
26. The method of claim 23 ,
wherein the cancer is breast cancer and
wherein administering the compound prevents the breast cancer from progressing to hormone refractory breast cancer.
27. The method of claim 23 ,
wherein the cancer is hormone sensitive breast cancer and
wherein administering the compound prevents the hormone sensitive breast cancer from progressing to hormone refractory breast cancer.
28. The method of claim 23 , wherein the cancer is selected from the group consisting of ovarian cancer, hormone sensitive ovarian cancer, and hormone refractory ovarian cancer.
29. The method of claim 1 ,
further comprising administering an antiestrogen to the subject,
wherein the compound is administered after administering the antiestrogen.
30. The method of claim 29 , wherein the compound is
31. The method of claim 29 , wherein the cancer is selected from the group consisting of breast cancer and ovarian cancer.
32. The method of claim 1 , further comprising administering a receptor modulator selected from the group consisting of an estrogen receptor modulator and a nuclear receptor modulator to the subject.